BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 22891404)

  • 1. Clinical efficacy and adverse effects of golimumab in the treatment of rheumatoid arthritis.
    Chovel-Sella A; Karplus R; Sella T; Amital H
    Isr Med Assoc J; 2012 Jun; 14(6):390-4. PubMed ID: 22891404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
    Boyce EG; Halilovic J; Stan-Ugbene O
    Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Oldfield V; Plosker GL
    BioDrugs; 2009; 23(2):125-35. PubMed ID: 19489653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
    Voulgari PV
    Expert Rev Clin Immunol; 2010 Sep; 6(5):721-33. PubMed ID: 20828280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Golimumab: A novel anti-TNF-alpha human monoclonal antibody for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
    Campas-Moya C
    Drugs Today (Barc); 2010 Jan; 46(1):13-22. PubMed ID: 20200692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany.
    Krüger K; Burmester GR; Wassenberg S; Bohl-Bühler M; Thomas MH
    BMJ Open; 2018 Jun; 8(6):e021082. PubMed ID: 29903793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Golimumab (simponi) for inflammatory arthritis.
    Med Lett Drugs Ther; 2009 Jul; 51(1316):55-6. PubMed ID: 19590489
    [No Abstract]   [Full Text] [Related]  

  • 8. [RETROSPECTIVE DATA ANALYSIS OF THE PATIENTS WITH INFLAMMATORY JOINT DISEASES TREATED WITH GOLIMUMAB IN CROATIA].
    Anić B; Babić-Naglić Ð; Grazio S; Kehler T; Kaliterna DM; Radoncić KM; Morović-Vergles J; Novak S; Prus V; Vlak T; Baresić M
    Reumatizam; 2015; 62(1):12-9. PubMed ID: 27024887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.
    Rotar Ž; Tomšič M; Praprotnik S;
    Clin Rheumatol; 2019 Feb; 38(2):297-305. PubMed ID: 30324406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    Kay J; Fleischmann R; Keystone E; Hsia EC; Hsu B; Zhou Y; Goldstein N; Braun J
    J Rheumatol; 2016 Dec; 43(12):2120-2130. PubMed ID: 27803138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Husni ME; Deodhar A; Schwartzman S; Chakravarty SD; Hsia EC; Leu JH; Zhou Y; Lo KH; Kavanaugh A
    Arthritis Res Ther; 2022 Mar; 24(1):73. PubMed ID: 35313978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Golimumab, the newest TNF-α blocker, comes of age.
    Papagoras C; Voulgari PV; Drosos AA
    Clin Exp Rheumatol; 2015; 33(4):570-7. PubMed ID: 25602858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
    Rossini M; Viapiana O; Orsolini G; Fracassi E; Idolazzi L; Gatti D; Adami S; Govoni M
    Reumatismo; 2015 Mar; 66(4):285-303. PubMed ID: 25829189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of golimumab in the treatment of arthritis.
    Fleischmann R
    Expert Opin Biol Ther; 2010 Jul; 10(7):1131-43. PubMed ID: 20504106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High 3-year golimumab survival in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: real world data from 328 patients.
    Thomas K; Flouri I; Repa A; Fragiadaki K; Sfikakis PP; Koutsianas C; Kaltsonoudis E; Voulgari PV; Drosos AA; Petrikkou E; Sidiropoulos P; Vassilopoulos D
    Clin Exp Rheumatol; 2018; 36(2):254-262. PubMed ID: 29148406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term golimumab persistence: Five-year treatment retention data pooled from pivotal Phase III clinical trials in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Weinstein CLJ; Meehan AG; Lin J; Briscoe SD; Govoni M
    Clin Rheumatol; 2023 Dec; 42(12):3397-3405. PubMed ID: 37751000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Golimumab - a new tool in the armoury against inflammatory arthritis.
    Ash Z; Emery P
    Ann Med; 2011 Mar; 43(2):133-41. PubMed ID: 21244218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
    Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
    Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
    Kay J; Fleischmann R; Keystone E; Hsia EC; Hsu B; Mack M; Goldstein N; Braun J; Kavanaugh A
    Ann Rheum Dis; 2015 Mar; 74(3):538-46. PubMed ID: 24344160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.